Skip to main content
SpringerLink
Log in

Prognostic and Predictive Gene Expression Signatures in Breast Cancer

  • Chapter
  • First Online:
Molecular Pathology of Breast Cancer

  • 1361 Accesses

Abstract

Breast cancer patients have varying prognoses and responses to treatment due to the heterogeneity of the disease. This chapter surveys the histopathological features, molecular markers, and multigene signatures used for prognosis and prediction of treatment response. The commercially available gene expression based assays for prognostication/prediction in ER+ breast cancer are briefly described and critically discussed. We analyze the underlying reasons for the comparable significance of these tests at the population level, while the tests are discordant for many individual patients. The current challenges to development of future assays are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, Ravdin P, Bugarini R, Baehner FL, Davidson NE, Sledge GW, Winer EP, Hudis C, Ingle JN, Perez EA, Pritchard KI, Shepherd L, Gralow JR, Yoshizawa C, Allred DC, Osborne CK, Hayes DF, Breast Cancer Intergroup of North America (2010) Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 11(1):55–65. doi:10.1016/S1470-2045(09)70314-6

    Google Scholar 

  • Badve SS, Baehner FL, Gray RP, Childs BH, Maddala T, Liu ML, Rowley SC, Shak S, Perez EA, Shulman LJ, Martino S, Davidson NE, Sledge GW, Goldstein LJ, Sparano JA (2008) Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol 26(15):2473–2481. doi:10.1200/JCO.2007.13.6424

    Article  PubMed  Google Scholar 

  • Bartlett JMS et al (2015) Abstract P4-11-07: comparison of multiparameter tests in the UK OPTIMA-Prelim trial. Cancer Res 57(9 Supplement):P4-11-07

    Google Scholar 

  • Barton S, Zabaglo L, A’Hern R, Turner N, Ferguson T, O’Neill S, Hills M, Smith I, Dowsett M (2012) Assessment of the contribution of the IHC4+ C score to decision making in clinical practice in early breast cancer. Br J Cancer 106(11):1760–1765. doi:10.1038/bjc.2012.166

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bloom HJ, Richardson WW (1957) Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11(3):359–377

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Cardoso F et al (2008) Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol 26(5):729–735

    Google Scholar 

  • Clark GM (2004) Diseases of the breast. Lippincott-Raven, Philadelphia

    Google Scholar 

  • Cufer T (2008) Which tools can I use in daily clinical practice to improve tailoring of treatment for breast cancer? The 2007 St. Gallen guidelines and/or Adjuvant! Online. Ann Oncol 19(Suppl 7):vii41–vii45. doi:10.1093/annonc/mdn439

    Google Scholar 

  • Cuzick J et al (2011) Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol 29(32):4273–4278

    Google Scholar 

  • Davies C et al (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381(9869):805–816

    Google Scholar 

  • D’Eredita G, Giardina C, Martellotta M, Natale T, Ferrarese F (2001) Prognostic factors in breast cancer: the predictive value of the Nottingham prognostic index in patients with a long-term follow-up that were treated in a single institution. Eur J Cancer 37(5):591–596. doi:S0959804900004354 [pii]

    Google Scholar 

  • Dodson A et al (2015) Risk of recurrence estimates with IHC4+C are tolerant of variations in staining and scoring: an analytical validity study. J Clin Pathol. doi:10.1136/jclinpath-2015-203212

    Google Scholar 

  • Dowsett M et al (2013) Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol 31(22):2783–2790

    Google Scholar 

  • Drukker CA, Elias SG, Nijenhuis MV, Wesseling J, Bartelink H, Elkhuizen P, Fowble B, Whitworth PW, Patel RR, de Snoo FA, van ‘t Veer LJ, Beitsch PD, Rutgers EJ (2014) Gene expression profiling to predict the risk of locoregional recurrence in breast cancer: a pooled analysis. Breast Cancer Res Treat 148(3):599–613. doi:10.1007/s10549-014-3188-z

    Google Scholar 

  • Dubsky P, Brase JC et al (2013) The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients. Br J Cancer 109(12):2959–2964

    Google Scholar 

  • Dubsky P, Filipits M et al (2013) EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. Ann Oncol 24(3):640–647

    Google Scholar 

  • Elston CW, Ellis IO, Pinder SE (1999) Pathological prognostic factors in breast cancer. Crit Rev Oncol Hematol 31(3):209–223. doi:S1040842899000347 [pii]

    Google Scholar 

  • Filipits M et al (2011) A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res 17(18):6012–6020

    Google Scholar 

  • Filipits M et al (2014) The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer. Clin Cancer Res 20(5):1298–1305

    Google Scholar 

  • Fisher ER, Anderson S, Redmond C, Fisher B (1993) Pathologic findings from the National Surgical Adjuvant Breast Project protocol B-06. 10-year pathologic and clinical prognostic discriminants. Cancer 71(8):2507–2514

    Article  CAS  PubMed  Google Scholar 

  • Fisher B, Dignam J, Tan-Chiu E, Anderson S, Fisher ER, Wittliff JL, Wolmark N (2001) Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes. J Natl Cancer Inst 93(2):112–120

    Article  CAS  PubMed  Google Scholar 

  • Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, O’Malley F, Simpson JF, Connolly JL, Hayes DF, Edge SB, Lichter A, Schnitt SJ (2000) Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124(7):966–978

    CAS  PubMed  Google Scholar 

  • Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC (2010) American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28(16):2784–2795. doi:10.1200/JCO.2009.25.6529

    Article  PubMed  PubMed Central  Google Scholar 

  • Harvey JM, Clark GM, Osborne CK, Allred DC (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17(5):1474–1481

    CAS  PubMed  Google Scholar 

  • Henson DE, Ries L, Freedman LS, Carriaga M (1991) Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer. The basis for a prognostic index. Cancer 68(10):2142–2149

    Article  CAS  PubMed  Google Scholar 

  • Hilsenbeck SG, Ravdin PM, de Moor CA, Chamness GC, Osborne CK, Clark GM (1998) Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat 52(1–3):227–237

    Article  CAS  PubMed  Google Scholar 

  • Ignatiadis M et al (2012) Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. J Clin Oncol 30(16):1996–2004

    Google Scholar 

  • Jakesz R et al (2007) Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst 99(24):1845–1853

    Google Scholar 

  • Jankowitz RC et al (2011) Prognostic utility of the breast cancer index and comparison to Adjuvant! Online in a clinical case series of early breast cancer. Breast Cancer Res 13(5):R98

    Google Scholar 

  • Kelly CM et al (2010) Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers. Cancer 116(22):5161–5167

    Google Scholar 

  • Kelly CM et al (2012) Agreement in risk prediction between the 21-gene recurrence score assay (Oncotype DX®) and the PAM50 breast cancer intrinsic Classifierâ„¢ in early-stage estrogen receptor-positive breast cancer. Oncologist 17(4):492–498

    Google Scholar 

  • Knauer M et al (2010) The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat 120(3):655–661

    Google Scholar 

  • Knight WA, Livingston RB, Gregory EJ, McGuire WL (1977) Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res 37(12):4669–4671

    CAS  PubMed  Google Scholar 

  • Langfelder P, Horvath S (2007) Eigengene networks for studying the relationships between co-expression modules. BMC Syst Biol 1:54

    Google Scholar 

  • Le Doussal V, Tubiana-Hulin M, Friedman S, Hacene K, Spyratos F, Brunet M (1989) Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer 64(9):1914–1921

    Article  PubMed  Google Scholar 

  • Liedtke C et al (2009) Genomic grade index is associated with response to chemotherapy in patients with breast cancer. J Clin Oncol 27(19):3185–3191

    Google Scholar 

  • Liu S, Chapman JA, Burnell MJ, Levine MN, Pritchard KI, Whelan TJ, Rugo HS, Albain KS, Perez EA, Virk S, Barry G, Gao D, O’Brien P, Shepherd LE, Nielsen TO, Gelmon KA (2015) Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial. Breast Cancer Res Treat 149(2):439–448. doi:10.1007/s10549-014-3259-1

    Article  CAS  PubMed  Google Scholar 

  • Ma X-J et al (2008) A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clin Cancer Res 14(9):2601–2608

    Google Scholar 

  • Mamounas EP et al (2008) Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial. J Clin Oncol 26(12):1965–1971

    Google Scholar 

  • Metzger-Filho O et al (2013) Genomic Grade Index (GGI): feasibility in routine practice and impact on treatment decisions in early breast cancer. In: Glynn SA (ed) vol 8(8). PLoS ONE, pp e66848

    Google Scholar 

  • Neville AM, Bettelheim R, Gelber RD, Save-Soderbergh J, Davis BW, Reed R, Torhorst J, Golouh R, Peterson HF, Price KN et al (1992) Factors predicting treatment responsiveness and prognosis in node-negative breast cancer. The International (Ludwig) Breast Cancer Study Group. J Clin Oncol 10(5):696–705

    CAS  PubMed  Google Scholar 

  • Nielsen TO et al (2010) A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res 16(21):5222–5232

    Google Scholar 

  • Olivotto IA, Bajdik CD, Ravdin PM, Speers CH, Coldman AJ, Norris BD, Davis GJ, Chia SK, Gelmon KA (2005) Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 23(12):2716–2725. doi:10.1200/JCO.2005.06.178 23/12/2716 [pii]

    Article  PubMed  Google Scholar 

  • Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27):2817–2826. NEJMoa041588 [pii]. doi:10.1056/NEJMoa041588

    Google Scholar 

  • Pereira H, Pinder SE, Sibbering DM, Galea MH, Elston CW, Blamey RW, Robertson JF, Ellis IO (1995) Pathological prognostic factors in breast cancer. IV: should you be a typer or a grader? A comparative study of two histological prognostic features in operable breast carcinoma. Histopathology 27(3):219–226

    Article  CAS  PubMed  Google Scholar 

  • Parker JS et al (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27(8):1160–1167

    Google Scholar 

  • Pertschuk LP, Feldman JG, Kim YD, Braithwaite L, Schneider F, Braverman AS, Axiotis C (1996) Estrogen receptor immunocytochemistry in paraffin embedded tissues with ER1D5 predicts breast cancer endocrine response more accurately than H222Sp gamma in frozen sections or cytosol-based ligand-binding assays. Cancer 77(12):2514–2519. doi:10.1002/(SICI)1097-0142(19960615)77:12<2514::AID-CNCR14>3.0.CO;2-V [pii] 10.1002/(SICI)1097-0142(19960615)77:12<2514::AID-CNCR14>3.0.CO;2-V

  • Piccart-Gebhart MJ, Sotiriou C (2007) Adjuvant chemotherapy—yes or no? Prognostic markers in early breast cancer. Ann Oncol 18(Suppl 12):xii2–7

    Google Scholar 

  • Prat A et al (2015) Prediction of response to neoadjuvant chemotherapy using core needle biopsy samples with the prosigna assay. Clin Cancer Res. doi:10.1158/1078-0432.CCR-15-0630

    Google Scholar 

  • Ravdin PM (1995) A computer based program to assist in adjuvant therapy decisions for individual breast cancer patients. Bull Cancer 82(Suppl 5):561s–564s

    Google Scholar 

  • Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, Gerson N, Parker HL (2001) Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19(4):980–991

    CAS  PubMed  Google Scholar 

  • Rhodes A, Jasani B, Balaton AJ, Miller KD (2000) Immunohistochemical demonstration of oestrogen and progesterone receptors: correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries. J Clin Pathol 53(4):292–301

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Rosen PP, Groshen S, Saigo PE, Kinne DW, Hellman S (1989) Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years. J Clin Oncol 7(9):1239–1251

    CAS  PubMed  Google Scholar 

  • Russo J, Frederick J, Ownby HE, Fine G, Hussain M, Krickstein HI, Robbins TO, Rosenberg B (1987) Predictors of recurrence and survival of patients with breast cancer. Am J Clin Pathol 88(2):123–131

    Article  CAS  PubMed  Google Scholar 

  • Saphner T, Tormey DC, Gray R (1996) Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14(10):2738–2746

    Google Scholar 

  • Sestak I et al (2013) Factors predicting late recurrence for estrogen receptor-positive breast cancer. J Natl Cancer Inst 105(19):1504–1511

    Google Scholar 

  • Sestak I et al (2014) Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score. J Clin Oncol 16 (8):916-922

    Google Scholar 

  • Sgroi DC, Carney E et al (2013) Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker. J Natl Cancer Inst 105(14):1036–1042

    Google Scholar 

  • Sgroi DC, Sestak I et al (2013) Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol 14(11):1067–1076

    Google Scholar 

  • Smith JA 3rd, Gamez-Araujo JJ, Gallager HS, White EC, McBride CM (1977) Carcinoma of the breast: analysis of total lymph node involvement versus level of metastasis. Cancer 39(2):527–532

    Article  PubMed  Google Scholar 

  • Sorlie T et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98(19):10869–10874

    Google Scholar 

  • Sotiriou C, Desmedt C (2006) Gene expression profiling in breast cancer. Ann Oncol 17(Suppl 10):x259–62

    Google Scholar 

  • Sotiriou C et al (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98(4):262–272

    Google Scholar 

  • Sparano JA et al (2015) Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med 151015072327001

    Google Scholar 

  • Tang G et al (2011) Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors. J Clin Oncol 29(33):4365–4372

    Google Scholar 

  • Toussaint J et al (2009) Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues. BMC Genomics 10(1):424

    Google Scholar 

  • van de Vijver MJ et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347(25):1999–2009

    Google Scholar 

  • van t Veer LJ et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871):530–536

    Google Scholar 

  • Venet D, Dumont JE, Detours V (2011) Most random gene expression signatures are significantly associated with breast cancer outcome. In: Rigoutsos I (ed) PLoS Comput Biol 7(10):e1002240

    Google Scholar 

  • Wirapati P et al (2008) Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 10(4):R65

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Applied and Computational Mathematics and Statistics, University of Notre Dame, Notre Dame, IN, 46556, USA

    Steven Buechler

  2. Joshua Edwards Professor of Pathology, Indiana University School of Medicine, Indianapolis, IN, USA

    Sunil Badve

Authors
  1. Steven Buechler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sunil Badve
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Steven Buechler .

Editor information

Editors and Affiliations

  1. Pathology & Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA

    Sunil Badve

  2. Indiana University School of Medicine, Dept of Pathology & Laboratory Medicine Indiana University School of Medicine, Indianapolis, Indiana, USA

    Yesim Gökmen-Polar

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Buechler, S., Badve, S. (2016). Prognostic and Predictive Gene Expression Signatures in Breast Cancer. In: Badve, S., Gökmen-Polar, Y. (eds) Molecular Pathology of Breast Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-41761-5_18

Download citation

Publish with us

Policies and ethics

Search

Navigation